drug · small molecule
sevabertinib
Marketedupdated 3mo agoby Bayer AG🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.
indications
investigational
NSCLC
all catalysts(1)
Trials studying sevabertinib
- phase3A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- —Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
- phase1A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 19, 2030
~4.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Oct 10, 2035compositionUS 10428063
FDA exclusivities (1)
- Nov 19, 2030NCENew Chemical Entity (5y)4.3y
News(1)
- Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 studyThis analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequ…onclive · 3mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that